Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 13/20 | 0.60 |
| ▸ | PDE4B | Q07343 | 9/20 | 0.60 |
| ▸ | PDE4C | Q08493 | 9/20 | 0.60 |
| ▸ | PDE4D | Q08499 | 9/20 | 0.60 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | CASP1 | P29466 | 1/20 | 0.48 |
| ▸ | GFER | P55789 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL426375 | 0.93 | PDE4A (0.64) | PDE4APDE4BPDE4CPDE4DNR3C1 | |
| SCHEMBL29648487 | 0.88 | PDE4A (0.59) | PDE4APDE4BPDE4CPDE4DGAA | |
| SCHEMBL30368528 | 0.88 | PDE4A (0.66) | PDE4APDE4BPDE4CPDE4DTSHR | |
| SCHEMBL25375126 | 0.87 | PDE4A (0.49) | PDE4APDE4BPDE4CPDE4DNR3C1 | |
| SCHEMBL30368558 | 0.85 | KDM1A (0.53) | PDE4APDE4BPDE4CPDE4DGAA | |
| SCHEMBL30368451 | 0.85 | ALDH1A1 (0.46) | PDE4APDE4BPDE4CPDE4DGAA | |
| SCHEMBL25375025 | 0.85 | PDE4A (0.46) | PDE4APDE4BPDE4CPDE4DGAA | |
| SCHEMBL30368709 | 0.85 | PDE4A (0.46) | PDE4APDE4BPDE4CPDE4DGAA | |
| SCHEMBL25377288 | 0.85 | PDE4A (0.49) | PDE4APDE4BPDE4CPDE4DTSHR | |
| SCHEMBL7052450 | 0.82 | PDE4A (0.71) | PDE4APDE4BPDE4CPDE4DNR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12509579-B2 | Thermoplastic resin and optical lens including same | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2025-12-30 | — | — | US | disclosed |
| CN-115996931-B | Cyclic diol compound, process for producing the compound, and use of the compound | 新日本理化株式会社 | 2025-04-01 | — | — | CN | disclosed |
| US-20230399510-A1 | THERMOPLASTIC RESIN AND OPTICAL LENS INCLUDING SAME | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2023-12-14 | — | — | US | disclosed |
| EP-4239010-A1 | THERMOPLASTIC RESIN AND OPTICAL LENS INCLUDING SAME | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2023-09-06 | — | — | EP | disclosed |
| CN-116323753-A | Thermoplastic resin and optical lens comprising the same | 三菱瓦斯化学株式会社 | 2023-06-23 | — | — | CN | disclosed |
| WO-2013068592-A1 | INHIBITORS OF CYSTATHIONINE BETA SYNTHASE TO REDUCE THE NEUROTOXIC OVERPRODUCTION OF ENDOGENOUS HYDROGEN SULFIDE | FONDATION JEROME LEJEUNE (FR) | 2013-05-16 | — | — | WO | disclosed |
| EP-0940387-B1 | PHENYLETHANOLAMINE COMPOUNDS USEFUL AS BETA3 AGONIST, PROCESS FOR PRODUCING THE SAME, AND INTERMEDIATES IN THE PRODUCTION OF THE SAME | MITSUBISHI PHARMA CORP (JP) | 2003-05-07 | — | — | EP | disclosed |
| US-6069176-A | PHENYLETHANOLAMINE COMPOUNDS WITH A BETA-3 ADRENERGIC RECEPTOR STIMULATING EFFECT, USE AS A THERAPY FOR URINARY INCONTINENCE | MITSUBISHI-TOKYO PHARMACEUTICALS, INC. (JP) | 2000-05-30 | — | — | US | disclosed |
| EP-0940387-A1 | PHENYLETHANOLAMINE COMPOUNDS USEFUL AS BETA3 AGONIST, PROCESS FOR PRODUCING THE SAME, AND INTERMEDIATES IN THE PRODUCTION OF THE SAME | TOKYO TANABE COMPANY LIMITED (JP) | 1999-09-08 | — | — | EP | disclosed |
| US-3888907-A | LOWER ALKYL ESTERS OF 2-(3,4-DIMETHOXYPHENYL)-4,6-DIOXOCYCLOHEXANE CARBOXYLIC ACID | HOFFMANN LA ROCHE | 1975-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12509579-B2 | Thermoplastic resin and optical lens including same | RIF1, POT1, LAS1L | PDE4A 4750/4885PDE4B 4714/4885PDE4C 4785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.